Benitec Biopharma financials
$9.75−2.69%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY26 Jun 30 | FY25 Jun 30 | FY24 Jun 30 | FY22 Jun 30 | FY21 Jun 30 | FY20 Jun 30 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $73.0K | $59.0K | $102.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $73.0K | $59.0K | $102.0K |
| Gross margin | — | — | — | 100.0% | 100.0% | 100.0% |
| Operating income | -$51.2M | -$41.8M | -$22.5M | -$17.9M | -$13.6M | -$8.3M |
| Net income | -$45.5M | -$37.9M | -$22.4M | -$18.2M | -$13.9M | -$8.3M |
| Net margin | — | — | — | −24942.5% | −23528.8% | −8111.8% |
| Diluted EPS | $-0.98 | $-1.05 | $-1.22 | $-37.91 | $-54.91 | $-137.70 |
| EBITDA | -$51.1M | -$41.7M | -$22.4M | -$17.7M | -$13.4M | -$8.1M |
| Operating cash flow | -$16.5M | -$23.6M | -$19.4M | -$15.9M | -$12.8M | -$7.5M |
| Free cash flow | -$16.6M | -$23.6M | -$19.6M | -$15.9M | -$13.1M | -$7.6M |
| Diluted shares | 46.6M | 36.2M | 18.4M | 0.5M | 0.3M | 0.1M |
Balance sheet
| Period end | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 | Jun 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $180.0M | $97.7M | $50.9M | $2.5M | $4.1M | $19.8M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $182.6M | $99.6M | $52.2M | $4.5M | $6.0M | $21.4M |
| Total liabilities | $5.6M | $2.3M | $5.0M | $4.3M | $3.1M | $1.4M |
| Shareholders' equity | $177.0M | $97.3M | $47.2M | $202.0K | $2.9M | $20.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology